Viibryd Dose Selection Was Weak Spot, But Sponsor’s Gamble Paid Off

“The inadequacy of dose exploration is clearly the ‘Achilles heel’ of this application,” Office of Drug Evaluation I Deputy Director Ellis Unger declared in his Jan. 21, 2011, decision memo for the approval of Clinical Data, Inc.’s antidepressant Viibryd (vilazodone).